JP2020503390A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503390A5 JP2020503390A5 JP2019557538A JP2019557538A JP2020503390A5 JP 2020503390 A5 JP2020503390 A5 JP 2020503390A5 JP 2019557538 A JP2019557538 A JP 2019557538A JP 2019557538 A JP2019557538 A JP 2019557538A JP 2020503390 A5 JP2020503390 A5 JP 2020503390A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- expression construct
- cells
- target cell
- cancer cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 55
- 102000004169 proteins and genes Human genes 0.000 claims 20
- 108090000623 proteins and genes Proteins 0.000 claims 20
- 230000001225 therapeutic effect Effects 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 14
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- 230000035897 transcription Effects 0.000 claims 8
- 238000013518 transcription Methods 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 210000003292 kidney cell Anatomy 0.000 claims 7
- -1 B AX Proteins 0.000 claims 5
- 230000032683 aging Effects 0.000 claims 5
- 230000001939 inductive effect Effects 0.000 claims 5
- 108090000397 Caspase 3 Proteins 0.000 claims 4
- 102100029855 Caspase-3 Human genes 0.000 claims 4
- 102100026548 Caspase-8 Human genes 0.000 claims 4
- 102100026550 Caspase-9 Human genes 0.000 claims 4
- 102100038023 DNA fragmentation factor subunit beta Human genes 0.000 claims 4
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 claims 4
- 101000983523 Homo sapiens Caspase-9 Proteins 0.000 claims 4
- 101000950965 Homo sapiens DNA fragmentation factor subunit beta Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000003308 immunostimulating effect Effects 0.000 claims 4
- 230000001105 regulatory effect Effects 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 3
- 102100027308 Apoptosis regulator BAX Human genes 0.000 claims 2
- 108050006685 Apoptosis regulator BAX Proteins 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 108010029697 CD40 Ligand Proteins 0.000 claims 2
- 102100032937 CD40 ligand Human genes 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102000000311 Cytosine Deaminase Human genes 0.000 claims 2
- 108010080611 Cytosine Deaminase Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 210000001789 adipocyte Anatomy 0.000 claims 2
- 210000000601 blood cell Anatomy 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 210000005265 lung cell Anatomy 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000034217 membrane fusion Effects 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 210000001625 seminal vesicle Anatomy 0.000 claims 2
- 210000004989 spleen cell Anatomy 0.000 claims 2
- 230000002103 transcriptional effect Effects 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 201000010653 vesiculitis Diseases 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 230000007717 exclusion Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762444360P | 2017-01-09 | 2017-01-09 | |
| US62/444,360 | 2017-01-09 | ||
| PCT/US2018/013033 WO2018129563A1 (en) | 2017-01-09 | 2018-01-09 | Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020503390A JP2020503390A (ja) | 2020-01-30 |
| JP2020503390A5 true JP2020503390A5 (enExample) | 2021-10-07 |
Family
ID=62790808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019557538A Pending JP2020503390A (ja) | 2017-01-09 | 2018-01-09 | 治療用タンパク質の標的細胞特異的な産生のため、および標的細胞に関連する疾患、状態、または障害の治療のための、膜融合性脂質ナノ粒子、ならびにその作製および使用のための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11525146B2 (enExample) |
| EP (1) | EP3565607A4 (enExample) |
| JP (1) | JP2020503390A (enExample) |
| CN (1) | CN110678208B (enExample) |
| AU (1) | AU2018206485B2 (enExample) |
| CA (1) | CA3047140A1 (enExample) |
| WO (1) | WO2018129563A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015024605A2 (pt) * | 2013-03-24 | 2017-07-18 | Oisin Biotechnologies | sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| CN110678208B (zh) | 2017-01-09 | 2024-04-05 | 奥依信生物技术公司 | 膜融合脂质纳米颗粒和制造方法以及用于产生治疗性蛋白质和用于治疗的用途 |
| CN112312918A (zh) * | 2018-04-18 | 2021-02-02 | 奥依信生物技术公司 | 促融合脂质纳米粒和制备其的方法以及其用于靶细胞特异性产生治疗蛋白和治疗与靶细胞有关的疾病、病况或障碍的用途 |
| KR20210043574A (ko) | 2018-07-09 | 2021-04-21 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 푸소좀 조성물 및 이의 용도 |
| CN113631718A (zh) | 2018-11-14 | 2021-11-09 | 旗舰先锋创新V股份有限公司 | 用于特定隔室货物递送的组合物和方法 |
| WO2020102503A2 (en) * | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
| WO2020163408A2 (en) * | 2019-02-04 | 2020-08-13 | Oisin Biotechnologies, Inc. | Fusogenic lipid nanoparticles for the target cell-specific production of rapamycin inducible therapeutic proteins |
| CN112521511B (zh) | 2020-12-07 | 2023-03-14 | 中山大学 | 一种含EB病毒gB蛋白的自组装纳米颗粒及其制备方法与应用 |
| CA3216353A1 (en) | 2021-04-08 | 2022-10-13 | Sana Biotechnology, Inc. | Cd8-specific antibody constructs and compositions thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69132032T2 (de) | 1990-11-23 | 2000-12-21 | Peptech Ltd., North Ryde | Verzögerung, verhinderung und/oder rückgängigmachen von zellalterung |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| DE69841002D1 (de) | 1997-05-14 | 2009-09-03 | Univ British Columbia | Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln |
| CA2303201A1 (en) * | 1997-08-20 | 1999-02-25 | Dnavec Research Inc. | Vectors for treating cancer |
| JP2002512002A (ja) | 1997-11-07 | 2002-04-23 | ダルハウジー、ユニバーシティー | 新規なレオウイルス由来タンパク質、このタンパク質をコードする核酸、およびその使用 |
| US6899870B1 (en) | 1998-03-11 | 2005-05-31 | Board Of Regents, The University Of Texas System | Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery |
| CA2352486A1 (en) | 1998-11-25 | 2000-06-02 | Genetica, Inc. | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
| CA2325088A1 (en) | 2000-12-01 | 2002-06-01 | Fusogenix Inc. | Novel membrane fusion proteins derived from poikilothermic reovirus |
| AU2002345658A1 (en) | 2001-06-13 | 2002-12-23 | Eastern Virginia Medical School | Methods for targeted expression of therapeutic nucleic acid |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| JPWO2006043354A1 (ja) * | 2004-10-20 | 2008-05-22 | 独立行政法人放射線医学総合研究所 | 組込型の低線量放射線誘導性ベクター |
| US20100299770A1 (en) | 2007-06-12 | 2010-11-25 | Selkirk Stephen M | Targeted cell death |
| BRPI0913047A2 (pt) | 2008-05-23 | 2013-03-05 | Siwa Corp | anticorpo monoclonal humanizado, seu uso, bem como aparelho e mÉtodo in vitro para promover processos regenerativos em uma cultura de tecido ou cultura de cÉlula |
| DK3338765T3 (en) | 2009-12-01 | 2019-03-04 | Translate Bio Inc | STEROID DERIVATIVE FOR THE SUPPLY OF MRNA IN HUMANGENETIC DISEASES |
| US9089520B2 (en) * | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| EP2600871A2 (en) | 2010-08-04 | 2013-06-12 | The Ohio State University | Methods for impairing the p53/hdm2 auto-regulatory loop in multiple myeloma development using mir-192, mir-194 and mir-215 |
| WO2012040825A1 (en) | 2010-09-29 | 2012-04-05 | Innovascreen Inc. | Recombinant polypeptides for membrane fusion and uses thereof |
| US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| US9687448B2 (en) | 2012-12-07 | 2017-06-27 | Alnylam Pharmaceuticals, Inc. | Nucleic acid lipid particle formulations |
| CN105142614A (zh) | 2013-03-14 | 2015-12-09 | 迪克纳制药公司 | 用于配制阴离子试剂的方法 |
| BR112015024605A2 (pt) * | 2013-03-24 | 2017-07-18 | Oisin Biotechnologies | sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo |
| DE112014003136A5 (de) * | 2013-07-01 | 2016-04-21 | Charité - Universitätsmedizin Berlin | Immortalisierte humane Chorionzelllinie sowie Verfahren zur Immortalisierung humaner Chorionzellen |
| EP3234144B1 (en) | 2014-12-15 | 2020-08-26 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
| GB201503133D0 (en) | 2015-02-24 | 2015-04-08 | Ucl Business Plc And Syncona Partners Llp | Chimeric protein |
| EP3297680A2 (en) | 2015-05-20 | 2018-03-28 | Yeda Research and Development Co. Ltd | Method of targeting senescent cells |
| CN110678208B (zh) | 2017-01-09 | 2024-04-05 | 奥依信生物技术公司 | 膜融合脂质纳米颗粒和制造方法以及用于产生治疗性蛋白质和用于治疗的用途 |
| CN112312918A (zh) | 2018-04-18 | 2021-02-02 | 奥依信生物技术公司 | 促融合脂质纳米粒和制备其的方法以及其用于靶细胞特异性产生治疗蛋白和治疗与靶细胞有关的疾病、病况或障碍的用途 |
| WO2020163408A2 (en) | 2019-02-04 | 2020-08-13 | Oisin Biotechnologies, Inc. | Fusogenic lipid nanoparticles for the target cell-specific production of rapamycin inducible therapeutic proteins |
-
2018
- 2018-01-09 CN CN201880015966.9A patent/CN110678208B/zh active Active
- 2018-01-09 JP JP2019557538A patent/JP2020503390A/ja active Pending
- 2018-01-09 US US16/476,865 patent/US11525146B2/en active Active
- 2018-01-09 AU AU2018206485A patent/AU2018206485B2/en active Active
- 2018-01-09 EP EP18736240.5A patent/EP3565607A4/en active Pending
- 2018-01-09 CA CA3047140A patent/CA3047140A1/en active Pending
- 2018-01-09 WO PCT/US2018/013033 patent/WO2018129563A1/en not_active Ceased
-
2022
- 2022-11-08 US US17/983,167 patent/US20230220422A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503390A5 (enExample) | ||
| IL321714A (en) | Novel artificial nucleic acid molecules | |
| Taguchi et al. | Current status of clinical trials assessing oncolytic virus therapy for urological cancers | |
| JP2008545406A5 (enExample) | ||
| MX2018011384A (es) | Arn de replicacion en trans. | |
| WO2018073393A3 (en) | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy | |
| CN102741405A (zh) | 提高基因表达的系统和保持有该系统的载体 | |
| RU2019107976A (ru) | Композиция вакцины | |
| SA522432139B1 (ar) | بروتينات ربط متعددة الخصوصية لمعالجة السرطان | |
| FI3461261T3 (fi) | Yksiketjuisen vaihtelevan fragmentin sisältäviä cd3:a sitovia proteiineja | |
| BRPI0411526A (pt) | vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos | |
| WO2012099805A3 (en) | Nanoparticle based immunological stimulation | |
| JP2018537087A5 (enExample) | ||
| Yao et al. | The application of multiple miRNA response elements enables oncolytic adenoviruses to possess specificity to glioma cells | |
| Hajeri et al. | Oncolytic adenoviruses: strategies for improved targeting and specificity | |
| WO2013026334A1 (zh) | 阻止细胞dna合成、抑制细胞增殖的多肽及其用途 | |
| Villanueva et al. | Translational reprogramming in tumour cells can generate oncoselectivity in viral therapies | |
| WO2021077794A1 (zh) | 可溶性Tim-3重组蛋白及其突变型蛋白的制备和应用 | |
| JP2006512284A5 (enExample) | ||
| Bina et al. | Impact of RGD peptide tethering to IL24/mda-7 (Melanoma Differentiation Associated Gene-7) on apoptosis induction in hepatocellular carcinoma cells | |
| CN101623498A (zh) | 基于肿瘤内皮标记物-8基因的双靶标肿瘤疫苗及其制备方法 | |
| EP4282490A3 (en) | Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy | |
| Wang et al. | Recombinant adenovirus KGHV500 and CIK cells codeliver anti-p21-Ras scFv for the treatment of gastric cancer with wild-type ras overexpression | |
| CN108715863B (zh) | 一种肿瘤靶向性载体pcTERT及其构建方法及其应用 | |
| Nishie et al. | Measles virus C protein facilitates transcription by the control of N protein-viral genomic RNA interaction in early phases of infection |